Efficacy, safety, and survival factors for sorafenib treatment in japanese patients with advanced hepatocellular carcinoma

Oncology (Switzerland)

Volumn 84, Issue 2, 2012, Pages 108-114

  Nakano, Masahito ^a   Tanaka, Masatoshi ^b   Kuromatsu, Ryoko ^a   Nagamatsu, Hiroaki ^c   Sakata, Kenji ^d   Matsugaki, Satoru ^e   Kajiwara, Masahiko ^f   Fukuizumi, Kunitaka ^g   Tajiri, Nobuyoshi ^h   Matsukuma, Norito ⁱ   Sakai, Terufumi ^j   Ono, Noriyuki ^k   Yano, Yoichi ^l   Koga, Hironori ^a   Kurogi, Junichi ^a   Takata, Akio ^a   Sumie, Shuji ^a   Satani, Manabu ^a   Yamada, Shingo ^a   Niizeki, Takashi ^a   Aino, Hajime ^a   Iwamoto, Hideki ^a   Torimura, Takuji ^a   Sata, Michio ^a   more..

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY MEDICAL CENTER   (Japan)

^c Yame General Hospital   (Japan)

^d Omuta City Hospital   (Japan)

^e Kyouaikai Tobata Kyouritsu Hospital   (Japan)

^f Asakura Medical Association Hospital   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^h Social Insurance Tagawa Hospital   (Japan)

ⁱ Department of Surgery   (Japan)

^j ST MARY S HOSPITAL   (Japan)

^k Chikugo City Hospital   (Japan)

^l Saga Social Insurance Hospital   (Japan)

more..

Author keywords

Hepatocellular carcinoma; Japanese; Sorafenib

Indexed keywords

PROTHROMBIN; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; JAPANESE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PYRIDINES; RAF KINASES; RISK FACTORS; SAFETY; SURVIVAL RATE;

EID: 84868605784     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000342650     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745-750.
3. Sherman M: Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25:143-154.
4. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K, Ko-suge T, Okada S, Takayasu K, Yamasaki S: Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998; 28:1241-1246.
5. Zhang BH, Yang BH, Tang ZY: Randomized controlled trial of screening for hepatocellu-lar carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422.
6. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Ku-mada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Mein-hardt G, Okita K: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresect-able hepatocellular carcinoma. Eur J Cancer 2011; 47:2117-2127.
7. Nagasue N, Uchida M, Makino Y, Takemoto Y, Yamanoi A, Hayashi T, Chang YC, Kohno H, Nakamura T, Yukaya H: Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterolog y 1993; 105: 488-494.
8. Yang Y, Nagano H, Ota H, Morimoto O, Na-kamura M, Wada H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Dono K, Umeshita K, Nakamori S, Wakasa K, Sakon M, Monden M: Patterns and clini-copathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 2007; 141: 196-202.
9. Llovet JM, Burroughs A, Bruix J: Hepatocel-lula r carcinoma. Lancet 2003; 362: 1907-1917.
10. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of he-patocellular carcinoma. Hepatology 2005; 42:1208-1236.
11. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
12. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
14. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
15. Wilhelm SM, Adnane L, Newell P, Villanue-va A, Llovet JM, Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-3140.
16. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group: Sora-fenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
17. Furuse J, Ishii H, Nakachi K, Suzuki E, Shi-mizu S, Nakajima K: Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99: 159-165.
18. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepa-tocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34.
19. Forner A, Reig ME, de Lope CR, Bruix J: Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30:61-74.
20. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CT-CAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-181.
21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, La-combe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
23. Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A: Hypoxia-induc e d des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 2010; 36: 161-170.
24. Kudo M, Ueshima K: Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology 2010; 78(suppl 1):154-166.
25. Kim R, Aucejo F: Radiologic complete response with sirolimus and sorafenib in a he-patocellular carcinoma patient who relapsed after orthotopic liver transplantation. J Gas-trointest Cancer 2011; 42:50-53.
26. Lynch TJ, Bell DW, Sordella R, Gurubhaga-vatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to ge-f itinib. N Engl J Med 2004; 350: 2129-2139.
27. Abou-Alfa GK, Schwartz L, Ricci S, Amado-ri D, Santoro A, Figer A, De Greve J, Douil-lard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB: Phase II study of sorafenib in patients with advanced hepato-cellular carcinoma. J Clin Oncol 2006; 24: 4293-4300.
28. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Ab-bruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ: Phase II placebo-controlled randomized discontinuation trial of sora-fenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:2505-2512.
29. Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK: Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161:1045-1051.
30. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP: Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13: 1001-1011.
31. Anderson R, Jatoi A, Robert C, Wood LS, Keating KN, Lacouture ME: Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009; 14:291-302.
32. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S, Tonini G: Early skin toxicity as a pred ic t ive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15:85-92.